Deep sleep could be key to forestalling slow declines in brain health that may one day lead to Alzheimer's disease, the most ...

NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble ...

The drug has been shown in preclinical studies to have the capability of penetrating the blood-brain barrier and subsequently ...

Dr. Schacterle is a highly regarded leader who has successfully led global regulatory and quality activities across multiple neurologic and psychiatric therapeutic areas and all stages of development, ...

BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

MRI has shown that increases in the white matter of the brain and ventricle volume may be risk factors for the progression of ...

We now find ourselves at a point where commercially available plasma biomarker tests are demonstrating an extremely high ...

A recent paper published in Nature Medicine sheds light on a remarkable case where Alzheimer's appears to have been medically acquired through the transmission of the amyloid-beta protein. Typically ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer ...